Galenea gets 2-year grant of US$1 mn from NIH

Galenea Corp, a fully-integrated CNS drug discovery company, has been awarded an NIH Challenge Grant in Health and Science Research (RC1) as part of the American Recovery and Reinvestment Act of 2009 (Recovery Act). This two-year grant from the National Institute of Mental Health addresses the specific topic of 'Screening Approaches to Identify Pharmacologic Treatments for Mental Disorders' within the challenge area of Translational Science. The grant provides approximately $1 million to support the development of an innovative model for predicting the activity of potential treatments for impaired cognition in diseases such as schizophrenia. The programme is part of Galenea's ongoing effort to pioneer new practices for objective measures in CNS drug discovery.